Critical Review: Profusa (NASDAQ:PFSA) versus Bioventus (NASDAQ:BVS)

Bioventus (NASDAQ:BVS) and Profusa (NASDAQ:PFSA) are both small-cap manufacturing companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Earnings and Valuation

This table compares Bioventus and Profusa”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$563.83 million	1.08	-$33.54 million	$0.12	61.33
Profusa	N/A	N/A	N/A	N/A	N/A

Profusa has lower revenue, but higher earnings than Bioventus.

Analyst Recommendations

This is a summary of recent ratings and price targets for Bioventus and Profusa, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0	1	0	0	2.00
Profusa	1	0	0	0	1.00

Volatility & Risk

Bioventus has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Profusa has a beta of -0.18, suggesting that its share price is 118% less volatile than the S&P 500.

Profitability

This table compares Bioventus and Profusa’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioventus	1.39%	26.38%	7.27%
Profusa	N/A	N/A	N/A

Insider & Institutional Ownership

62.9% of Bioventus shares are held by institutional investors. Comparatively, 9.8% of Profusa shares are held by institutional investors. 33.0% of Bioventus shares are held by insiders. Comparatively, 21.6% of Profusa shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Bioventus beats Profusa on 8 of the 8 factors compared between the two stocks.

About Bioventus

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company’s restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician’s office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

About Profusa

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.